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A b s t r a c t  
Poorly water soluble drugs such as quetiapine fumarate (QF) offer challenges in developing a solid 
dosage form such as tablets with adequate bioavailability. The objective of the present work is to 
develop a solid dosage form for quetiapine nanoparticles in order to increase the saturation 
solubility, rate of dissolution so that the oral bioavailability is enhanced. Quetiapine fumarate is a 
BCS class II drug, hence its oral bioavailability is dissolution limited. To enhance the oral 
bioavailability a nanoparticle formulation of QF was prepared by using high pressure 
homogenization. The nanosuspension prepared was converted into dry powder by using spray 
drying. The nanosuspension and spray dried nanoparticles are characterized for particle size, 
polydispersity index, zeta potential, saturation solubility, drug content, dissolution rate, solid state 
characterization such as X-ray diffraction(XRD), Differential scanning calorimetry(DSC), infrared(IR), 
scanning electron microscopy(SEM), transmission electron microscopy(TEM). The spray dried 
nanoparticles were blended with excipients to convert into solid dosage form such as tablets. The 
compressed tablets were evaluated for physical parameters,assay anddissolution was compared 
with the commercial QF formulation. Solid state characterization data showed loss of drug 
crystallinity after homogenization. The novel dosage form has shown significant increase in the rate 
of dissolution when compared to microparticle formulation in discriminating medium. In-vivo studies 
have shown that the rate and extent of absorption of nanoparticle formulation was significantly high 
when compared to its microparticleformulation when administered in rats. 
Keywords: Quetiapine Fumarate, Nanoparticles, high pressure homogenization, Particle size. 
Introduction 
Poor aqueous solubility is major challenge in achieving the required 
oral bioavailability. A major hurdle that has prevented 
commercialization of many promising poorly soluble drugs is 
dissolution rate limited bioavailability [1].The major limitations of 
using a poorly soluble drug are high dose and higher administration 
frequency that may results in the side effects of the drugs [i.It has 
been reported in the literature that drug solubility and rate of 
dissolution have impact on the rate and extent of the bioavailability 
[2].Thus there is need for improvement of the bioavailability of such 
poor soluble drugs. Increasing drug solubility and stability through 
appropriate formulation approaches can lead to increased 
therapeutic efficacy of the drug. Many approaches are used to 
improve the solubility and dissolution properties of poorly soluble 
active ingredients including salt formation, formation of 
nanoparticles, pH adjustment, use of surfactants, inclusion 
complexes, use of oily formulations, use of self-emulsifying drug 
delivery systems, formation of co-precipitates with hydrophilic 
polymers, co-milling with hydrophilic excipients, to name a few. 
Among these the pharmaceutical particle size technology appear to 
be mostly employed to improve the poor aqueous solubility of 
poorly soluble drugs that limits in vivo bioavailability owing to its low 
dissolution rate in the gastrointestinal fluid after oral administration 
[3].Apart from conventional micronizing methods to reduce the 
particle size, nanotechnology appears to be promising method to 
enhance solubility and thereby the bioavailability because the 
particle size reduction increases the surface area [4].There are 
various ways in which nanoparticles of poorly water-soluble 
molecules are generated [5-8]. Alternatively, nanoparticles can be 
successfully generated using drug-fragmentation processes such 
as homogenization [9,10],microfluidation [11] or milling [12]. The 
main disadvantage of jet mill, bead or pearl millare the 
polydispersity of the product requiring subsequent removal of 
microparticles or abrasion of pearls in a mill. In the field of 
nanotechnology, polymer based nanoparticles have become 
prominent area of current research and development due to their 
ease of preparation [13].In this study high pressure homogenization 
technique is used as it is simple, fast and cost effective 
reproducible technique [14]. To prepare an effective solid dosage 
form from a drug nanosuspension, it is important that the 
nanosuspension is first dried and the dried nanoparticles should go 
back to their original particle size when reconstituted in an aqueous 
system [15]. Reported literature shows that the nanoparticles 
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improve the oral bioavailability of poorly bioavailable drugs due to 
their specialized uptake mechanism which may also prevent first 
pass metabolism [16] Quetiapine fumarate) is a psychotropic agent 
belonging to a chemical class, the dibenzothiazepine derivatives. 
Quetiapine fumarate is a BCS class II drug having poor solubility 
and having only 9% bioavailability [ii]. The chemical designation is 
2-[2-(4-dibenzo [b,f] [1,4]thiazepin-11-yl-1-piperazinyl) ethoxy]-
ethanol fumarate (2:1) (salt) and used to treat schizophrenia and 
bipolar disorder. The US FDA [United States Food and Drug 
Administration] approved label shows two major boxed warnings 
such as a) Increased Mortality in Elderly Patients with Dementia-
Related Psychosis and b) Suicidal Thoughts and Behaviors.The 
bioavailability of quetiapine is marginally affected by administration 
with food, with Cmaxand AUC values increased by 25% and 15%, 
respectively. The main objective of the current work is to evaluate 
the effect of particle size reduction on solubility, dissolution and 
bioavailability of quetiapine fumarate so that there can be a 
possibility of reducing the dose and address the dose related side 
effects. 
 
Materials and Methods 
 
Materials 
 
Quetiapine fumarate was procured from Dr Reddys Laboratories 
limited (Hyderabad, Inida). Mannitol was purchased from Roquette, 
Polyvinyl pyrrolidone [PVP K-30] was purchased from BASF 
(Germany); sodium lauryl sulfate was purchased from JRS, 
crospovidone and sodium starch glycolate were obtained from ISP 
and Grain Processing corporation. All other chemicals were of 
analytical grade. 
 
Methods 
 
Preparation of nanosuspension 
 
High pressure homogenization technique was used to produce the 
nanoparticles. Different batches of nanosuspension of 100 ml batch 
size were prepared by using combination of steric and electrostatic 
stabilizers. The drug suspension was prepared by dissolving the 
stabilizers in purified water followed by dispersing the drug 
quetiapine fumarate with constant stirring to prevent the lump 
formation. The drug suspension was first subjected to high shear 
homogenization process for about 15 minutes so that a 
homogeneous drug suspension was obtained. By subjecting to high 
shear homogenization it has been observed that there is reduction 
of the particle size of the drug to submicron level. This drug 
suspension at this level (i.e. before subjecting to high pressure 
homogenization process) is referred to a drug microparticle 
suspension and used to compare with the nanosuspension in the 
characterization studies. This homogenous drug suspension was 
subjected to high pressure homogenization process, wherein the 
drug suspension is passed through a narrow gap in the 
homogenizer at high pressure such as 750 ă 1000 bar pressure. 
The drug suspension was continuously subjected to high pressure 
homogenization in a recirculation mode for about 90 minutes. This 
process converts submicron particles into nanoparticles. To 
produce stable nanosuspension a combination of steric and 
electrostatic stabilizers has been used. The concentration of the 
stabilizers used and process of the homogenization process was 
optimized. The stability of the nanosuspension was evaluated upon 
storage at 2-8 ĈC and room temperature for a period of one week. 
Based on the particle size data, physical stability in terms of zeta 
potential, poly dispersity index at initial and on stability the 
formulation NS-04, NS-08 and NS-11 were selected for scaleup. 
These selected formulations were scaled to 1 L batch size wherein 
the drug suspension was prepared in the same manner as 
described above and subjected to high pressure homogenization 
for a period of 90 minutes. After homogenization the suspension 
was collected and stored at below temperature of 25 ĈC until further 
processing. 
Table 1: Composition of Quetiapine Fumarate Nanosuspension. 
 
Composition No. Composition (% w/v) Batch size/ Purified water 
in mL  Drug  SLS  PVP HPC HPMC 
NS-01 2.5 1 3 - - 100
NS-02 5 1 3 - - 100
NS-03 5 0.5 3 - - 100
NS-04 5 0.75 5 - - 100
NS-05 5 1 - 2.5 - 100
NS-06 5 0.5 - 5 - 100
NS-07 5 0.75 - 5 - 100
NS-08 5 0.75 - 5 - 250
NS-09 5 1 - - 2.5 250
NS-10 5 0.5 - - 5 250
NS-11 5 0.75 - - 5 250
NS-12 5 0.75 5 - - 1000
NS-13 5 0.75 - 5 - 1000
NS-14 5 0.75 - - 5 1000
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Characterization of the nanosuspension 
 
The nanosuspension obtained was characterized for particle size, 
zeta potential and polydispersity index.The particle size, which is 
represented in terms of d10, d50, d90 affects the solubility of the 
poorly soluble drug. The mean particle size (d50, ie 50 % of 
particles are having size less than this value) of the 
nanosuspension before drying was estimated in triplicate by using 
Zeta sizer- Nano ZS, Malvern Instruments UK) at room 
temperature. A refractive index of 1.65 was used for particle size 
analysis. Nanosuspension was added to the sample dispersion unit 
(deionized water) and stirred at 2000 rpm to reduce the 
interparticulate aggregation and laser obscuration range was 
maintained between 10-20 %. The samples were adequately 
diluted with deionized water and placed in electrophoretic cell and 
measurement was carried out with help of software. The particle 
size was measured after performing the experiments in triplicates. 
The particle size of drug in dried nanoparticles was analyzed by 
adding water to dried nanoparticles (so that the surface stabilizers, 
re-dispersants are in dissolved state and only drug in dispersed 
form) followed by dilution with water to obtain suitable 
concentrations for measurement in the same manner as carried out 
for the nanosuspension. 
 
Zeta Potential 
 
A prerequisite to achieve an enhancement of oral bioavailability 
with drug nanocrystals is that crystals are finely dispersed in the gut 
and do not aggregate. In case they start aggregation, the 
bioavailability decreases with increasing aggregate formation. This 
is attributed to the fact that they lose special properties of 
nanoparticles such as their adhesive property to the mucosal wall. 
Therefore it is necessary to prepare nanosuspensions with a 
physical stability as high as possible. Surface charge properties of 
the nanosuspensions are studied through zeta potential. The value 
of particle surface charge indicates the stability of nanosuspensions 
at the macroscopic level. A minimum zeta potential of μ30 mV is 
required for electrostatically stabilized nanosuspensions [17,18] 
and a minimum of μ20 mV for steric stabilization [19]. The zeta 
potential values are commonly calculated by determining the 
particle's electrophoretic mobility and then converting the 
electrophoretic mobility to the zeta potential [20].  
Zeta potential of the nano suspension has been analyzed in 
Malvern zeta sizer after diluting nanosuspension with water to 
obtain suitable concentration for measurement. Further the zeta 
potential of the dried nanoparticles is obtained by adding water to 
the dried nanoparticles and diluted with water to obtain suitable 
concentration for measurement. The diluted sample was added in 
specialized zeta cell and the same procedure as that of particle 
size was carried out. 
 
Production of dried nanoparticles 
 
Spray drying process was used to convert the nanosuspension into 
dried nanoparticles. Buchi mini spray dryer B-290 is used for this 
process. Spray drying is a process where in dry powder is obtained 
from a drug solution or suspension by rapidly drying with a hot gas 
such as nitrogen or oxygen etc. 
The nanosuspension (batch no. NS-12) prepared as above is spray 
dried using lactose as bulking agent. The resultant suspension was 
spray dried at inlet temperature of 140 ĈC, nitrogen pressure 5 
kg/cm2and liquid suspension feed rate 6-10 ml/minute. Prior to 
spray drying process, lactose is dissolved in the drug suspension 
as bulking agent and the composition is shown in table 2. For the 
comparison study, the drugmicroparticle suspension also subjected 
to spray drying process in similar manner as carried out for drying 
the nanosuspension. The difference between microparticle 
suspension and nanosuspension is that microparticle suspension is 
not subjected to particle size reduction in high pressure 
homogenizer. 
 
Table 2: Composition of the dried nanoparticles* 
Ingredients Quantity /Tablet (mg)
Quetiapine Fumarate 25.00
Polyvinyl pyrrolidone 12.5
Sodium lauryl sulfate 5
Water equivalent to  0.5 mL
Bulking agent/Redispersant
Lactose 50
             *the dried nanoparticles means the spray dried nanosuspension after incorporating lactose as the bulking agent or redispersants. 
 
Characterization of dried nanoparticles 
 
The dried nanoparticles and microparticles are characterized for 
particles size, zeta potential, poly dispersity index. Further the dried 
nanoparticlesare further subjected to solid state characterization 
such as X-ray powder diffraction, differential scanning calorimeter, 
Fourier transform infra-red spectroscopy, Scanning electron 
microscopy, drug content, saturation solubility, dissolution profile.  
 
X-ray Powder diffraction (XRD) 
Gubbala  et al. International Journal of Drug Delivery 8 (2) 37-49 [2016] 
 
 
  
PAGE | 40 |
 
 
The dried nanoparticles were characterized for X-ray powder 
diffraction to study the change in the crystallinity of the drug after 
subjecting to particle size reduction by high pressure 
homogenization process. X-ray diffraction pattern was recorded 
using over a 2-theta range of 3 ă 45 Ĉ using the X-ray diffraction 
model X'Pert MPD Model, Phillips, Holland using the Cu-target X-
ray tube and Xe-filled detector. The operating conditions were 
voltage 40 kV; current 30 mA; scanning speed 1/min.  
 
Differential Scanning Calorimetry (DSC)  
 
DSC is a method wherein the difference in the amount of heat 
required to increase the temperature of a sample and reference is 
measured as a function of temperature. DSC  analysis give add on 
to the observation of the XRD data for any change in the 
crystallinity of the drug after processing in high pressure 
homogenizer. DSC scans of the Quetiapine fumarate drug, the  
physical mixture of quetiapine, PVP, SLS and lactose and dried 
nanoparticles obtained by spray drying,have been studied using 
DSC- Shimadzu 60 with TDA trend line software. All samples were 
weighed (8-10 mg) and heated at a scanning rate of 20ĈC/min 
under dry air flow (100 ml/min) between 25Ĉ C and 200Ĉ at 
10ĈC/minute.  
 
Fourier Transform Infra-Red (FTIR) Spectroscopy 
 
Generally there are two regions in the infra-red region one is 
frequency region (1500 -4000 cm-1) and the second is finger print 
region (1500-400 cm-1), In the frequency region the corresponding 
peaks of the functional groups is being observed. And in the finger 
print region a series of the absorption bands are observed due to 
bending vibrations within the molecules and this region is very 
unique to each compound. The infra-red (IR) spectroscopy is an 
identification test generally used to study the compatibility of the 
drug with different excipients used while preparing the formulation, 
because it has been observed that when there is incompatibility 
there is shift in the characteristic peaks of different functional 
groups. In this analysis, the spectra corresponding to different 
functional groups is captured and if the IR spectra of the test 
formulation is identical to that of the drug and excipients, then it is 
understood that the drug is compatible with the excipients used in 
the formulation. 
The pure drug quetiapine, physical mixture of quetiapine, PVP, SLS 
and lactose and dried nanoparticles obtained by spray drying have 
been characterized for IR. The sample for IR analysis has been 
prepared by using disks of drug and Potassium Bromide (KBr) in 
1:100 ratio, using Shimadzu Fourier Transform Infra-Red 
spectrometer over wave number range of 400 to 4000 cm-1. 
 
Scanning Electron Microscopy [SEM] 
 
The scanning electron microscopy is used to study the morphology 
of the drug and the nanoparticles prepared. In this analysis the 
images of the sample are obtained by scanning the sample with the 
focused beam of the scattered electrons. The sample for the SEM 
analysis is prepared by applying the sample on the carbon rape 
stuck to the aluminium stub followed by applying a 5nm gold 
coating onto the sample. The sample prepared is subjected 
scanning electron microscopy, using model QUANTA 250 
FA867operated at the low vacuum with a LFD detector and 60 Pa 
pressure 
The morphology of the raw quetiapine fumarate, nanosuspension 
and dried nanoparticles was examined with the scanning electron 
microscopy. 
 
Transmission electron microscopy [TEM] 
 
Transmission electron microscopy is used to study the internal 
composition of the sample as the sample is scanned with the 
focused beam of transmitted electrons and has higher resolution. 
Hence TEM gives information like nanoparticle size information, 
crystallization, stress in addition to morphology.  TEM analysis of 
the nanosuspension prepared has been carried out in FEI 
Tecnai™ transmission electron microscope, G2 series.A droplet of 
sample diluted 1:100 in deionised water was dried on a carbon on 
copper TEM grid and were imaged in the TEM 
 
Saturation Solubility 
 
Saturation solubility gives an idea about the maximum amount of 
drug dissolved in the media. This study is useful particularly for 
poor soluble drugs. Saturation solubilityof Quetiapine Fumarate, 
spray dried microparticles and nanoparticle was carried out in 0.1 N 
HCl, 4.5 acetate buffer, 6.8 phosphate buffer and purified water. 
For determination of the saturation solubility, excess amount of the 
drug or dried nanoparticles have been added to 100 ml of media 
maintained at 37 ĈC and shaken onrotary shake flask for a period of 
24 hours. The samples are centrifuged for about 10 minutes at 
4000 rpm. The supernatant was collected and filtered through 0.22 
øm nylon membrane filter, diluted with diluents (methanol and 
acetonitrile in 1:1 ratio) and analyzed using HPLC (waters Alliance 
HPLC system USA) method same as that used for determination of 
drug content.  
 
Preparation of the Quetiapine Fumarate tablet 
 
The spray dried nanoparticles were mixed with the extragranular 
materials to form the final blend for compression. The extragranular 
materials include the disintegrant, glidant, lubricant. Four different 
disintegrants such as sodium starch glycolate, pregelatinized 
starch, crospovidone, croscarmellose sodium. Colloidal silicon 
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dioxide is used as a glidant and magnesium stearate is used as a 
lubricant. Firstly the spray dried nanoparticles blended with 
disintegarnt, glidant in double cone blender for about 25 minutes to 
form unlubricated blend. Finally the magnesium stearate is added 
to the unlubricated blend and blended for about 5 minutes to form 
final lubricated blend. This lubricated blend is compressed into 
tablets using 8 mm round punches using 8-station cadmach 
compression machine. 
 
Table 3: Composition of the tablets 
Ingredients Composition mg/tablet
 *NF-1 NF-2 NF-3 NF-4 MF-1**
Spray dried nanoparticles$ 92.5 92.5 92.5 92.5 92.5
Croscarmellose sodium 10 - - - -
pregelatinized starch - 10 - - -
Crospovidone - - 10 - -
Sodium starch glycolate - - - 10 10
Colloidal silicon dioxide 1 1 1 1 1
Talc 1 1 1 1 1
Magnesium stearate 0.5 0.5 0.5 0.5 0.2
Total weight 105 105 105 105 105
*NF:represents the tablet formulation prepared by using the spray dried nanoparticles with different disintegrants. 
**MF: represent the tablet formulation prepared by using the spray dried nanoparticles with sodium starch glycolate as disintegrant. 
$92.5 mg of the spray dried nanoparticles or microparticles contain 25 mg of quetiapine fumarate. 
 
Evaluation of Quetiapine tablets 
 
The physical parameters of the tablet such as tablet hardness, 
thickness, disintegration time, friability have been measured. The 
tablet hardness was measured using a hardness tester (Model: 8M, 
Dr. SchleunigerPharmatron, USA). Each hardness value reported 
is an average of ten measurements. The disintegration time was 
measured in purified water at 37 μ 0.5ĈC, using a disintegration 
tester (Model: ED2L, Electrolab, India). The disintegration time 
reported is an average of six measurements. Tablet friability was 
measured as the percentage weight loss of 20 tablets after 100 
revolutions using a friabilator (Model: EF2, electrotab, India). 
 
Drug content 
 
The tablet formulation prepared as above was evaluated for drug 
content by HPLC. The drug content of the tablet formulation 
prepared by using spray dried nanoparticles and microparticles was 
determined to know if there is any loss of drug during spray drying 
process. The drug content was determined by high pressure liquid 
chromatography (HPLC) method. Each tablet formulation was 
taken in volumetric flask and dissolved in diluents comprising 
water: acetonitrile in 20:80 ratiowith the help of sonication. Then the 
solution is subjected to centrifugation at the speed of 3000 rpm for 
about 10 minutes. Then this solution was filtered 
throughDurapore0.45 øm PVDF membrane filter and was analyzed 
by HPLC. The mobile phase consists of mixture of potassium di 
hydrogen orthophosphate, acetonitrile, tetrahydrofuran, triethyl 
amine pH adjusted to 6.4 with KOH solution. Chromatographic 
separation was accomplished using an Xterra Column RP8 3.5 øm; 
4.6X150 mm column. The mobile phase was pumped isocratically 
at a flow rate of 1.5 ml/minute during analysis and maintained at a 
column temperature of 50 ĈC and detection wavelength of 217 nm. 
 
In-Vitro Dissolution Study 
 
Quetiapine fumarate is shown to have pH dependent solubility with 
highest solubility in acidic medium and decreasing the solubility as 
the pH is increasing. The tablets prepared above using nano and 
microparticles are tested for rate of dissolution. The media chosen 
is pH 6.8 phosphate buffer as this pH was found to be 
discriminating media. The dissolution profiles of tablet formulation 
prepared using nanoparticles, microparticles and commercial 
tablets were determined in a USP apparatus II in 900ml phosphate 
buffer pH 6.8, at 37μ0.5ĈC with a paddle rotation speed at 50 rpm. 
Samples were filtered through a 0.22μm nylon membrane filter 
(Millipore, Bedford, MA) and assayed for drug content in the same 
manner as carried out for drug content. 
 
In-vivo pharmacokinetic study 
 
Male wistar rats weighing about 250 g were used for the 
pharmacokinetic study. The rats were fasted overnight with the free 
access to water. The animal experiments were carried out in 
accordance with the guidelines provided by institutional Animal 
Care and Ethics committee.All animalexperiments were approved 
by CPCSEA and IAEC. Eight rats were divided into two groups one 
is test and other group is reference. The test group received the 
suspension comprising spray dried nanoparticles and the reference 
group received the suspension comprising drug microparticles 
using oral gavage at a dose level of 10 mg/kg. Rodent feed was 
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returned after 3 hours post dosing. Blood samples have been 
collected from retro orbital vein at predetermined time intervals 0, 
0.5,1, 3, 5, 8, 10 and 24 hours post dosing. The blood samples 
were collected into centrifuge tubes upto 0.5 ml. Collected blood 
samples were immediately centrifuged at 9000 rpm for about 15 
minutes. The serum separated at top with theblood cells depositing 
at thebottom of the tube. The supernatant pale yellow color plasma 
is collected using micropipette. Approximately 0.3 -0.5 ml of the 
plasma has been collected into polypropylene vials and stored in 
freezer temperature at -20 ĈC until the analysis. 
 
Plasma Analysis/ Bioanalysis 
 
From the plasma the proteins should be separated. For the 
extraction of the proteins, to 250 øl of plasma, 50 øl of internal 
standard, 10 øl of lamotrigine was added into a centrifuge tube. To 
this 2 ml of acetonitrile is added and subjected to cyclomixer for 
about 15 seconds. Then the tubes are subjected to vertex for about 
2 minutes and finally centrifuge for about 3 minutes at 3200 pm 
speed. After the centrifugation the organic layer is collected. About 
10øl of the organic layer is injected into HPLC and analysis was 
carried out.  
Chromatographic conditions: 
Column                                   : KROMOSIL 250 4.6ø 5mm  
Mobile phase composition      :   Buffer   : Acetonitrile 55:45 
Flow rate    : 1 ml/min 
Injection volume   : 20 øl 
Run time    : 8 min 
Detection wavelength  : 254 nm 
Column temperature   : 30 Àc  
Sample temperature  : 5 Àc 
Diluent    :  water : methanol 50:50 
Buffer was prepared by dissolving potassium dihydrogen 
phosphate in water to make 0.02 N KH2PO4. Analytical data was 
acquired by Empower 2 software. Standard curves were obtained 
from linear square regression analysis of drug/internal standard 
peak area ratio as a function of plasma concentration versus time 
data was analyzed, and the oral pharmacokinetic data were 
developed. 
 
Results and Discussion 
 
Particle size, Polydispersity index and Zeta potential 
 
The quetiapine nanosuspension with different steric stabilizers and 
electrostatic stabilizers have been prepared and characterized.  
Selection of stabilizers is very important because these 
nanoparticles try to form aggregate and destabilize. From the 
particle size data as shown in table 4 it has been observed that 
among different concentrations of electrostatic stabilizers ie 
compositions NS-02, NS-03, NS-04 which are at concentration of 
1%, 0.5 % and 0.75% of electrostatic stabilizers, the composition 
with 0.75 % concentration has shown least particle size of d50 as 
112 nm and d90 as 220 nm. Hence with these concentrations of 
SLS, three different steric stabilizers at concentration of 5% have 
been evaluated. From the particle size data of compositions NS-04, 
NS-08, NS-011 has shown mean particle size (d50) as 112, 145 
and 127 nm respectively. Hence these three compositions has 
scaled up to 1 litre batch size and again characterized for particle 
size wherein d50 was 107,176,154 nm and was matching with the 
small batch size. All the compositions have been exposed to 
stability conditions of 2-8 ĈC and 25/60 % RH for about 1 week 
duration and similar trend was observed on stability. The 
formulation with PVP and SLS as stabilizers at concentration of 5% 
and 0.75 % has shown mean particle size as 210 and 198 at 2-8 ĈC 
and 25/60 %^ RH conditions respectively.  
 
 
Table 4: Particle size (nm) of nanosuspensions 
 
Formulation code Initial 1 week 2-8 ĈC 1 week 25 ĈC/60 % RH
 d10 d50 d90 d10 d50 d90 d10 d50 d90
NS-01 10 224 375 108 399 607 119 653 1350
NS-02 12 173 564 74.4 355 516 98 521 687
NS-03 258 484 821 88 210 345 101 417 569
NS-04 51 112 220 88 210 245 136 198 286
NS-05 63.5 368 490 139 366 1460 480 612 743
NS-06 12.5 249 845 27 339 793 89 417 1210
NS-07 19.6 161 427 103 532 775 108 520 1050
NS-08 71 145 594 51 176 314 89.5 357 542
NS-09 56 181.5 496 133 594 843 135 616 1000
NS-10 55 392 517 169 205 242 66 271 360
NS-11 64 127 287 136 198 286 191 339 503
NS-12 49 107 206 44 104 214 53 108 210
NS-13 79 176 641 71 891 1510 64 1348 1547
NS-14 70 154 314 68 216 674 93 545 1310
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The polydispersity index (as shown in table 5) of the compositions 
with PVP and HPC as steric stabilizers have shown the PDI as 0.27 
and 0.283 respectively owing to the narrow particle size 
distribution, however on stability it has been observed that there is 
aggregation in the compositions with HPC thus showing higher 
PDI. And the composition with PVP was found to stabilize the 
nanoparticles, thus it retained narrow particle size distribution with 
PDI of 0.3 and 0.4 at 2-8ĈC & 25ĈC/60% RH respectively. This was 
also represented by the zeta potential data wherein the ZP of the 
compositions with HPC and HPC was reduced on stability when 
compared to initial but the ZP of the composition with PVP was 
retained owing to its stability. Based on the above data, the 
composition with PVP and SLS as primary and secondary 
stabilizers is selected for further processing. 
 
Table 5 Polydispersity index and Zeta potential of nanosuspensions 
Formulation code Initial 1 week 2-8 ĈC 1 week 25 ĈC/60 % RH 
 PDI ZP PDI ZP PDI ZP 
NS-01 0.353 14.4 0.7 10.7 0.565 8.22 
NS-02 0.518 9.34 0.61 16.7 0.71 16.9 
NS-03 0.566 10.9 0.51 11.7 0.7 14.6 
NS-04 0.27 34 0.3 36.7 0.4 35.9 
NS-05 1 29.4 0.6 16.7 1 8.61 
NS-06 0.86 22 0.43 8.61 0.6 10.7 
NS-07 0.4 34 0.53 30.1 0.736 25 
NS-08 0.283 34.2 0.365 28.8 0.655 21 
NS-09 0.54 21.9 0.61 14.1 0.627 9 
NS-10 0.93 21 1 18.5 0.8 10.9 
NS-11 0.48 31.9 0.4 32.1 0.4 21 
NS-12* 0.25 42.5 0.28 34 0.4 32.5 
NS-13 0.36 31.4 0.5 27.1 1 25.2 
NS-14 0.31 32.1 0.7 21.2 0.89 20.5 
 
It is very important that the drug nanoparticles prepared should 
retain their particle size on stability as well as after converting into 
powder form or when dispersed in the water or physiological fluid. 
Spray drying technique was used to convert suspension into 
powder form using lactose as redispersant or bulking agent and 
characterized. From the particle size data as shown in table 6 of 
the spray dried nanoparticles was observed that after drying also 
the particles retained its particle size and are stable wherein d50 is 
103 nm and PDI as 0.29 and ZP as 36 mV. 
 
Table 6: Characterization of spray dried nanoparticles and spray dried drug microparticles 
 Particle size distribution PDI ZP 
 d10 d50 d90  
Nanoparticles 54 103 198 0.29 36
Microparticles 313 1070 4970 1 21
 
Solid state characterization 
 
The change in the solid state of the drug after homogenization and 
drying has been evaluated using XRD, DSC. The X-ray diffraction 
pattern of the drug quetiapine fumarate, dried nanoparticles, 
physical mixture (of quetiapine fumarate, polyvinyl pyrrolidone, 
sodium lauryl sulfate) are compared in Figure 1. The XRD pattern 
of the formulation shows absence of the characteristic peaks of the 
drug, thus drug lost its crystallinity. This is further confirmed by the 
DSC data, wherein the characteristic endotherm of the drug has 
been lost in the formulation owing to loss of its crystallinity.  
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Figure 1: XRD diffractograms for A: API Quetiapine fumarate, B: Physical mixture of quetiapine fumarate, PVP, SLS and lactose C: spray dried 
nanoparticles. 
 
 
 
 
 
 
Figure 2: DSC curves of A: Quetiapine Fumarate; B: Physical Mixture of quetiapine fumarate, PVP, SLS and lactose and C: spray dried 
nanoparticles. 
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The TEM image of the nanosuspension for the composition NS-12 
as shown in Figure 5 indicated that the nanosuspension has 
irregular shaped particles of almost uniform size not showing any 
aggregation, this is supported by the low polydispersity index of the 
nanosuspension. TEM further confirms the nanoparticle size. 
 
 
Figure 5 :TEM image of the nanosuspension. 
 
 
 
Saturation solubility 
 
The saturation solubility of the drug quetiapine fumarate, spray 
dried microparticles and spray dried nanoparticles has been 
evaluated in different pH media i.e 0.1 N HCl, 4.5 acetate buffer, 
6.8 phosphate buffer and water. Solubility data has been captured 
in table 7. The results indicated that the drug the solubility of drug 
quetiapine fumarate decreases with the increase in the pH, this is 
because the drug is showing pH dependent solubility. The 
saturation solubility of the spray dried nanoparticles was 
significantly higher when compared to the pure drug or the spray 
dried microparticles. 
 
Table 7: Saturation solubility of drug quetiapine fumarate and spray dried microparticles and nanoparticles. 
 
 
 
 
 
 
 
 
 
*solubility was analyzed in respective solvents comprising PVP and SLS. 
 
 
Conversion of spray dried nanoparticles into tablet 
dosage form 
 
To enhance the tabletting properties of the spray dried 
nanoparticles, these nanoparticles were blended with the 
extragranular materials and compressed into tablets. Four different 
Solvents Solubility mg/ml  
 Drug quetiapine 
fumarate* 
spray dried 
microparticles 
Spray dried 
nanoparticles 
0.1 N HCl 9 20 44 
4.5 acetate buffer 4 6 15 
6.8 phosphate buffer 3.1 3.2 6 
Water 2.6 3.1 5.4 
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disintegrants were evaluated. The physical properties of the tablets 
are shown in Table 4. For comparison the spray dried 
microparticles were also compressed and evaluated for physical 
properties. Out of all the four disintegrants, sodium starch glycolate 
showed fastest disintegration time i.e. 5 minutes and 
croscarmellose showed the slow disintegration time i.e 12 minutes. 
Whereas the tablets prepared by the microparticles along with 
sodium starch glycolate as disintegrant showed still slowest 
disintegration time ie> 15 minutes. Further all the tablets have 
shown uniform tablet weight, thickness and drug content, hardness 
in the range of 5-9 kp and friability less than 0.1 % showing good 
strength of the tablets.  
 
Tablet 8: Physical properties of the tablets 
 Tablet weight(mg)* Thickness 
(mm)@ 
Hardness (kp)$ Disintegration time 
minutes)** 
Friability (%) Drug 
content 
NF-1 105 μ 5 2.0 μ 0.2 7 .0 μ 0.5 12μ 1.6 0.09 98.2
NF-2 105 μ 5 2.0 μ0.2 6.5 μ 0.4 8 μ 1.0 0.06 97.3
NF-3 105 μ 4 2.0 μ 0.2 5.0 μ 0.7 9  μ 0.5 0.07 97.8
NF-4 105 μ 3 2.0 μ 0.2 9.0 μ 0.2 5 μ 0.4 0.02 99.1
MF-1 105 μ 4 2.0 μ 0.2 10 μ 0.5 > 15 0.03 98.3
* Tablet weight range is determined by weighing 20 tablets individually. 
@ Thickness range is determined by taking thickness of 5 tablets individually. 
$ Hardness range is determined by taking hardness of 5 tablets individually. 
**Disintegration time range is determined on 6 individual tablets. 
 
In-vitro Evaluation 
 
Dissolution profiles were determined for the tablets prepared by 
spray dried microparticles; nanoparticles and the commercial 
tablets in pH 6.8 phosphate media (as this is the discriminating 
media). As shown in figure 6, it has been observed that rate of the 
dissolution of all the nanoformulations is significantly higher than 
the commercial tablet and also high than the microparticle 
formulation. Out of all the nanoformulations the formulation NF-4 
showed fastest dissolution profile. The rate and extent of the 
dissolution of the drug from the tablet dosage of nanoparticles is 
more than 80 % and NF-4 is 97 % at end of the dissolution study 
whereas the commercial tablet showed only 45 % and microparticle 
formulation showed 63 % of dissolution. The formulation with 
sodium starch glycolate as disintegrant has shown almost complete 
release of drug at the end of dissolution but the tablets with other 
disintegrants has shown incomplete release of the drug.  
 
Figure 6: Comparative dissolution profile 
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In-vivo evaluation 
 
Both the microparticle and the nanoparticle formulation has been 
evaluated for the single dose parallel pharmacokinetic study in the 
male wistar rats. And the results have been shown in Table 9. From 
the data it has been observed that maximum plasma concentration 
for the microparticle and nanoparticle formulation is 0.0822 μ 0.005 
and 0.3632 + 0.002 respectively.  The results also has been 
represented in figure 7, which shows approximately 2.5 folds 
increase in the AUC (0-24 h) and 4.5 folds increase in the plasma 
concentration of quetiapine fumarate with reduction in time required 
to achieve the maximum plasma concentration from 1.32 hr to 1.0 
hr. The significant increase in the plasma concentration and oral 
bioavailability can be attributed to increase in the saturation 
solubility and rate of dissolution due to particle size reduction to the 
nanoparticle size.  
 
Table 9: Pharmacokinetic parameters (mean μ SD, n=4) of Quetiapine Fumarate. 
 
Parameter Microparticles formulation Nanoparticle formulation 
AUC (0-24)  0.6125 μ 0.005 1.5147 μ 0.005 
Cmax (øg/mL) 0.0822 μ 0.005 0.3632 μ 0.002 
Tmax ( hr) 1.32 1.0 
 
 Figure 7: Comparative plasma concentration Vs time profile for the nanoparticle suspension and microparticle suspension in wistar rats. 
 
 
Conclusions 
 
From this study it has been observed that the formulation 
containing quetiapine nanoparticles has been successfully 
prepared by high pressure homogenization technique combined 
with spray drying technique. From the solid state characterization 
data ie XRD and DSC data, it has been observed that drug after 
processing for particle size reduction followed by spray drying the 
drug has lost its crystallinity. The significant enhancement in 
saturation solubility and rate of dissolution can be attributed to the 
particle size reduction which is further confirmed by TEM analysis. 
The in-vivo pharmacokinetic study in rats has shown 4.5 folds 
increase in the plasma concentration and 2.5 folds increase in the 
oral bioavailability with the reduction in time required to achieve the 
maximum plasma concentration. The increase in the rate of 
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dissolution can be correlated to improvement in absorption of the 
quetiapine fumarate in the gastro intestinal tract of the rats. The 
enhancement of the oral bioavailability of the nanoparticle 
formulation can be attributed to increase in the surface area 
obtained by particle size reduction. This enhancement in the oral 
bioavailability can be explored on the strong possibility of the dose 
reduction of quetiapine fumarate so that dose related side effects of 
this drug can be minimized. 
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